Special Issue "Purposing and Repurposing of Antimalarial Agents"
Deadline for manuscript submissions: closed (31 July 2020) | Viewed by 37680
Interests: drug design; synthesis of biologically active agents; antimalarial agents; anticancer agents; prodrugs; polymer–drug conjugates; biofilm eradication; antiviral agents
Interests: antimalarial and anticancer agents
Special Issues, Collections and Topics in MDPI journals
Despite enormous efforts made by the scientific community, malaria remains one of the leading causes of morbidity and mortality in tropical areas. Increasing resistance to the currently available antimalarial drugs has made the need to develop new and efficient agents even more urgent. Practically all currently used antimalarial drugs were developed directly or indirectly from two naturally occurring substances: quinine and artemisinin. Derivatization of clinically approved antimalarial drugs is still a popular strategy in the search of novel antiplasmodial agents. For example, modification of primaquine led to the discovery of tafenoquine and bulaquine, while derivatization of artemisinin was awarded by several clinically important drugs (dihydroartemisinin, artesunate, and artemether).
Finding novel therapeutic indications for already approved drugs is one of possible strategies in the search of novel medicines. Antimalarial drugs and/or their derivatives are useful in the treatment of autoimmune diseases, parasitemia, and tuberculosis. In addition, anticancer effects of 14 registered antimalarial drugs have been reported, and many of them are under evaluation in clinical trials, alone or in combination with conventional anticancer drugs.
Contributions to this Special Issue may cover the rational design and synthesis of novel compounds with antiplasmodial activity or derivatives of known antimalarial agents with antimalarial (purposing) or other applications (repurposing). Short communications, original research papers or review articles are welcomed.
Prof. Dr. Branka Zorc
Prof. Dr. Zrinka Rajić
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Novel antiplasmodial agents
- Repurposing of antimalarial drugs
- Antimalarial agents in cancer therapy